Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution
- PMID: 2201682
Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution
Abstract
The mode of binding of acetyl-pepstatin to the protease from the human immunodeficiency virus type 1 (HIV-1) has been determined by x-ray diffraction analysis. Crystals of an acetyl-pepstatin-HIV-1 protease complex were obtained in space group P2(1)2(1)2 (unit cell dimensions a = 58.39 A, b = 86.70 A, c = 46.27 A) by precipitation with sodium chloride. The structure was phased by molecular replacement methods, and a model for the structure was refined using diffraction data to 2.0 A resolution (R = 0.176 for 12901 reflections with I greater than sigma (I); deviation of bond distances from ideal values = 0.018 A; 172 solvent molecules included). The structure of the protein in the complex has been compared with the structure of the enzyme without the ligand. A core of 44 amino acids in each monomer, including residues in the active site and residues at the dimer interface, remains unchanged on binding of the inhibitor (root mean square deviation of alpha carbon positions = 0.39 A). The remaining 55 residues in each monomer undergo substantial rearrangement, with the most dramatic changes occurring at residues 44-57 (these residues comprise the so-called flaps of the enzyme). The flaps interact with one another and with the inhibitor so as to largely preserve the 2-fold symmetry of the protein. The inhibitor is bound in two approximately symmetric orientations. In both orientations the peptidyl backbone of the inhibitor is extended; a network of hydrogen bonds is formed between the inhibitor and the main body of the protein as well as between the inhibitor and the flaps. Hydrophobic side chains of residues in the body of the protein form partial binding sites for the side chains of the inhibitor; hydrophobic side chains of residues in the flaps complete these binding sites.
Similar articles
-
Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution.Science. 1989 Dec 1;246(4934):1149-52. doi: 10.1126/science.2686029. Science. 1989. PMID: 2686029
-
Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures.Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8387-91. doi: 10.1073/pnas.90.18.8387. Proc Natl Acad Sci U S A. 1993. PMID: 8378311 Free PMC article.
-
Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.Science. 1990 Aug 3;249(4968):527-33. doi: 10.1126/science.2200122. Science. 1990. PMID: 2200122
-
Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates.Eur J Biochem. 1997 Oct 15;249(2):523-30. doi: 10.1111/j.1432-1033.1997.00523.x. Eur J Biochem. 1997. PMID: 9370363
-
Crystal structures of Aspergillus oryzae aspartic proteinase and its complex with an inhibitor pepstatin at 1.9A resolution.J Mol Biol. 2003 Mar 7;326(5):1503-11. doi: 10.1016/s0022-2836(03)00078-0. J Mol Biol. 2003. PMID: 12595261
Cited by
-
HIV-2 protease is inactivated after oxidation at the dimer interface and activity can be partly restored with methionine sulphoxide reductase.Biochem J. 2000 Mar 1;346 Pt 2(Pt 2):305-11. Biochem J. 2000. PMID: 10677347 Free PMC article.
-
SPROUT: a program for structure generation.J Comput Aided Mol Des. 1993 Apr;7(2):127-53. doi: 10.1007/BF00126441. J Comput Aided Mol Des. 1993. PMID: 8320553
-
Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes.J Comput Aided Mol Des. 1997 Sep;11(5):425-45. doi: 10.1023/a:1007996124545. J Comput Aided Mol Des. 1997. PMID: 9385547
-
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.J Med Chem. 2009 Sep 24;52(18):5732-47. doi: 10.1021/jm9009394. J Med Chem. 2009. PMID: 19715320 Free PMC article.
-
Biochemical Characterization of Human Retroviral-Like Aspartic Protease 1 (ASPRV1).Biomolecules. 2020 Jul 6;10(7):1004. doi: 10.3390/biom10071004. Biomolecules. 2020. PMID: 32640672 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources